Methods relating to treatment of atheroaclerosis
AssigneeCambridge Theranostics Ltd.
InventorIvan Petyaev
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification of lipid oxidising antibodies as a key pathogenic factor in atherosclerotic disorders. These disorders may be treated by inhibiting this antibody mediated lipid oxidation and methods and means for identifying and producing inhibitory agents are provided.
Claims33
A method for obtaining an inhibitor of antibody-mediated lipid oxidation comprising:
- (a) contacting a lipid-oxidising antibody and a test compound wherein said compound is a potential inhibitor of antibody-mediated lipid oxidation;
- and
- (b) measuring lipid oxidation activity of said lipid oxidising antibody in the presence of said compound
A method for screening for an inhibitor of antibody-mediated lipid oxidation comprising:
- (a) admixing a lipid oxidising antibody and a lipid antigen in the presence of a test compound, said test compound being suspected of being an inhibitor of antibody-mediated lipid oxidation;
- and
- (b) determining any binding of said lipid antigen to said lipid oxidising antibody in the presence of said test compound whereby said test compound is an inhibitor of antigen-mediated lipid oxidation when a lack of binding or decrease in binding of said antigen to said antibody in the presence of said test compounds i detected.
A method for screening for an inhibitor of antibody-mediated lipid oxidation comprising:
- (a) admixing a lipid oxidising antibody and a lipid antigen in the presence of a test compound, said test compound being suspected of being an inhibitor of antibody-mediated lipid oxidation;
- and
- (b) determining oxidation of said lipid antigen to said lipid oxidising antibody in the presence of said test compound whereby said test compound is an inhibitor of antigen-mediated lipid oxidation when a lack of oxidation or decrease in oxidation of said antigen in the presence of said test compound is detected.
A method of identifying a test compound as an agent which modulates the binding and/or activity of a lipid oxidising antibody comprising:
- (a) admixing said lipid oxidising antibody and a lipid antigen in the presence of said test compound;
- and
- (b) determining any binding of said lipid antigen to said lipid oxidising antibody in the presence of said test compound whereby said test compound is a modulator of the binding and/or activity of the lipid oxidising antibody when a lack of binding or decrease in binding of said antigen to said antibody in the presence of said test compound is detected.
A method of identifying a test compound as an agent which modulates the binding and/or activity of a lipid oxidising antibody comprising:
- (a) admixing said lipid oxidising antibody and a lipid antigen in the presence of said test compound;
- and
- (b) determining oxidation of said lipid antigen to said lipid oxidising antibody in the presence of said test compound whereby said test compound is a modulator of the binding and/or activity of the lipid oxidising antibody when a lack of oxidation or decrease in oxidation of said antigen in the presence of said test compound is detected.
A method of identifying a test compound as an agent which modulates the level and/or activity of a lipid oxidising antibody, comprising:
- (a) introducing a test compound into the vascular system of an animal having elevated levels of lipid oxidising antibodies;
- and
- (b) determining the level or activity of said lipid oxidising antibodies whereby said test compound is a modulator of the level and/or activity of the lipid oxidising antibody when a lack of lipid oxidising antibodies or a decrease in the activity or level of said antibodies in the presence of said test compound is detected.
A method producing a modulator of lipid oxidising antibody binding and/or activity comprising:
- (a) admixing said lipid oxidising antibody and a lipid antigen in the presence of said test compound which is suspected of being a modulator of lipid oxidising antibody binding and/or activity;
- (b) determining any binding of said lipid antigen to said lipid oxidising antibody in the presence of said test compound whereby said test compound is a modulator of the binding and/or activity of the lipid oxidising antibody when a lack of binding or decrease in binding of said antigen to said antibody in the presence of said test compounds is detected;
- and
- (c) selecting said test compound which is a modulator of lipid oxidising antibody binding and/or activity.
A method of producing a modulator of lipid oxidising antibody binding and/or activity comprising:
- (a) admixing said lipid oxidising antibody and a lipid antigen in the presence of said test compound which is suspected of being a modulator of lipid oxidising antibody binding and/or activity;
- (b) determining oxidation of said lipid antigen to said lipid oxidising antibody in the presence of said test compound whereby said test compound is a modulator of the binding and/or activity of the lipid oxidising antibody when a lack of oxidation or decrease in oxidation of said antigen in the presence of said test compounds is detected;
- and
- (c) selecting said test compound which is a modulator of lipid oxidising antibody binding and/or activity.
A method of producing a modulator of lipid oxidising antibody binding and/or activity comprising:
- (a) introducing a test compound into the vascular system of an animal having elevated levels of lipid oxidising antibodies;
- and
- (b) determining the level or activity of said lipid oxidising antibodies whereby said test compound is a modulator of the level and/or activity of the lipid oxidising antibody when a lack of lipid oxidising antibodies or a decrease in the activity or level of said antibodies in the presence of said test compound is detected, and;
- (c) selecting said test compound which is a modulator of lipid oxidising antibody binding and/or activity.
A method of formulating a modulator of lipid oxidising antibody binding and/or activity into a composition with a pharmaceutically acceptable excipient comprising:
- (a) admixing said lipid oxidising antibody and a lipid antigen in the presence of said test compound which is suspected of being a modulator of lipid oxidising antibody binding and/or activity;
- (b) determining any binding of said lipid antigen to said lipid oxidising antibody in the presence of said test compound whereby said test compound is a modulator of the binding and/or activity of the lipid oxidising antibody when a lack of binding or decrease in binding of said antigen to said antibody in the presence of said test compound is detected;
- (c) selecting said test compound which is a modulator of lipid oxidising antibody binding and/or activity;
- and
- (d) formulating said selected test compound which is a modulator with a pharmaceutically acceptable excipient.
A method of formulating a modulator of lipid oxidising antibody binding and/or activity into a composition with a pharmaceutically acceptable excipient comprising:
- (a) admixing said lipid oxidising antibody and a lipid antigen in the presence of said test compound which is suspected of being a modulator of lipid oxidising antibody binding and/or activity;
- (b) determining oxidation of said lipid antigen to said lipid oxidising antibody in the presence of said test compound whereby said test compound is a modulator of the binding and/or activity of the lipid oxidising antibody when a lack of oxidation or decrease in oxidation of said antigen to said antibody in the presence of said test compounds is detected;
- (c) selecting said test compound which is a modulator of lipid oxidising antibody binding and/or activity;
- and
- (d) formulating said selected test compound which is a modulator with a pharmaceutically acceptable excipient.
A method of formulating a modulator of lipid oxidising antibody binding and/or activity into a composition with a pharmaceutically acceptable excipient comprising:
- (a) introducing a test compound into the vascular system of an animal having elevated levels of lipid oxidising antibodies;
- and
- (b) determining the level or activity of said lipid oxidising antibodies whereby said test compound is a modulator of the level and/or activity of the lipid oxidising antibody when a lack of lipid oxidising antibodies or a decrease in the activity or level of said antibodies in the presence of said test compound is detected,
- (c) selecting said test compound which is a modulator of lipid oxidising antibody binding and/or activity;
- and
- (d) formulating said selected test compound which is a modulator with a pharmaceutically acceptable excipient.
A method for preparing a pharmaceutical composition for treating an athersclerotic condition comprising;
- i) identifying a compound which is an agonist/antagonist of a lipid oxidising antibody,
- ii) synthesising the identified compound, and;
- iii) incorporating the compound into a pharmaceutical composition.
An animal model for an atherosclerotic condition comprising a non-human animal having lipid oxidising antibodies in the vascular system thereof,
- wherein said lipid oxidising antibodies are elicited by the introduction of one or more Chlamydial cell antigens into the vascular system of the animal.
Dependencies are inferred from the claim text.